{"id":"W4411643311","doi":"10.1016/j.esmoop.2025.105200","title":"71O Profiling antibody-drug conjugate (ADC) target expression in high-grade serous ovarian cancer (HGSOC): Opportunities for targeted treatment strategies","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; BeiGene; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; European Commission; Seagen; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Amgen; Deciphera Pharmaceuticals; Sociedad Española de Oncología Médica; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Mersana Therapeutics; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Serous ovarian cancer; Antibody-drug conjugate; Serous fluid; Ovarian cancer; Medicine; Conjugate; Cancer research; Drug; Antibody; Targeted therapy; Oncology; Monoclonal antibody; Internal medicine; Cancer; Immunology; Pharmacology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001678059,0.0001266301,0.0002076161,0.0005756333,0.0001113984,0.0003897658,0.00006276476,0.0001955069,0.001063507],"category_scores_gemma":[0.0002319096,0.00007798815,0.00008915427,0.0004023404,0.0001086597,0.0001502656,0.0001214139,0.0001542151,0.0002199592],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002496373,"about_ca_system_score_gemma":0.000114515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001007025,"about_ca_topic_score_gemma":0.001810685,"domain_scores_codex":[0.9998975,0.00001903165,0.000006332353,0.00001283704,0.00003739409,0.00002692527],"domain_scores_gemma":[0.9999208,0.00001919944,0.00002057515,0.000005565744,0.00002330869,0.00001042017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0007281315,0.0000750308,0.04364152,0.0002023845,0.00003370373,0.0002338494,0.0001273869,0.0004851276,0.9140541,0.0001776479,0.0002650443,0.03997613],"study_design_scores_gemma":[0.00003614515,0.001170951,0.164025,0.00003585162,0.0001346875,0.001543062,0.0004075994,0.004769669,0.8134645,0.0002077139,0.01419124,0.00001352992],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927787,0.003304541,0.001407062,0.00006157369,0.000008139684,0.00003437065,0.000303692,0.00003367447,0.002068204],"genre_scores_gemma":[0.9949124,0.001428817,0.001487976,0.00003428792,0.000006458886,0.00001989525,0.0003483889,0.000006072488,0.001755792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001063507,"threshold_uncertainty_score":0.003557742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0628592540817787,"score_gpt":0.3691242001253307,"score_spread":0.306264946043552,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}